Synedgen is focused on developing first-in-class therapeutics aimed at restoring mucosal barrier function, particularly in the gastrointestinal (GI) tract. Their lead asset, MIIST305, is an orally delivered therapeutic designed to repair GI mucosal injury, enhance GI function, and mitigate inflammation and damage. The company employs a unique Multivalent Innate Immune Signaling Target (MIIST) platform that promotes the repair and regeneration of mucosal and dermal barriers, thereby modulating immune responses to manage inflammation and infection. This innovative approach has led to a diversified drug pipeline that addresses various forms of damage, including those caused by radiation and chemical exposure.

In addition to GI health, Synedgen's technology extends to multiple therapeutic areas, including pulmonary disease, sinus care, and ophthalmic health. Their discovery platform has yielded promising candidates, such as MIIST113, which is currently in Phase 2 clinical trials for pulmonary conditions. The company is also developing therapies to alleviate gastrointestinal side effects from cancer treatments and has received funding from the National Eye Institute to address severe eye injuries. Synedgen's commitment to innovation is supported by a robust intellectual property portfolio, ensuring protection for their platform and therapeutic candidates as they advance through clinical development.

United States

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

Synedgen

Company Details